The Gene and Protein Expression of the Main Components of the Lipolytic System in Human Myocardium and Heart Perivascular Adipose Tissue. Effect of Coronary Atherosclerosis.
Adipose Tissue
/ metabolism
Cell Cycle Proteins
/ metabolism
Coronary Artery Disease
/ metabolism
Gene Expression
/ genetics
Heart
/ physiology
Humans
Lipase
/ metabolism
Lipid Metabolism
/ genetics
Lipolysis
/ genetics
Male
Middle Aged
Myocardium
/ metabolism
RNA, Messenger
/ metabolism
Triglycerides
/ metabolism
G0/G1 switch protein 2
adipose triglyceride lipase
comparative gene identification-58
hormone-sensitive lipase
multivessel coronary artery disease
perivascular adipose tissue
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
22 Jan 2020
22 Jan 2020
Historique:
received:
13
12
2019
revised:
09
01
2020
accepted:
20
01
2020
entrez:
26
1
2020
pubmed:
26
1
2020
medline:
7
10
2020
Statut:
epublish
Résumé
The aim of our study was to examine the regulation of triacylglycerols (TG) metabolism in myocardium and heart perivascular adipose tissue in coronary atherosclerosis. Adipose triglyceride lipase (ATGL) is the major TG-hydrolase. The enzyme is activated by a protein called comparative gene identification 58 (CGI-58) and inhibited by a protein called G0/G1 switch protein 2 (G0S2). Samples of the right atrial appendage and perivascular adipose tissue were obtained from two groups of patients: 1-with multivessel coronary artery disease qualified for coronary artery bypass grafting (CAD), 2-patients with no atherosclerosis qualified for a valve replacement (NCAD). The mRNA and protein analysis of ATGL, HSL, CGI-58, G0S2, FABP4, FAT/CD36, LPL, β-HAD, CS, COX4/1, FAS, SREBP-1c, GPAT1, COX-2, 15-LO, and NFκβ were determined by using real-time PCR and Western Blot. The level of lipids (i.e., TG, diacylglycerol (DG), and FFA) was examined by GLC. We demonstrated that in myocardium coronary atherosclerosis increases only the transcript level of G0S2 and FABP4. Most importantly, ATGL, β-HAD, and COX4/1 protein expression was reduced and it was accompanied by over double the elevation in TG content in the CAD group. The fatty acid synthesis and their cellular uptake were stable in the myocardium of patients with CAD. Additionally, the expression of proteins contributing to inflammation was increased in the myocardium of patients with coronary stenosis. Finally, in the perivascular adipose tissue, the mRNA of G0S2 was elevated, whereas the protein content of FABP-4 was increased and for COX4/1 diminished. These data suggest that a reduction in ATGL protein expression leads to myocardial steatosis in patients with CAD.
Identifiants
pubmed: 31979197
pii: ijms21030737
doi: 10.3390/ijms21030737
pmc: PMC7037202
pii:
doi:
Substances chimiques
Cell Cycle Proteins
0
RNA, Messenger
0
Triglycerides
0
Lipase
EC 3.1.1.3
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : National Science Center
ID : 2016/23/D/NZ3/01660
Organisme : Medical University of Bialystok
ID : N/ST/ZB/15/005/1153 and N/ST/ZB/16/004/1153
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
Int J Mol Sci. 2018 Mar 10;19(3):
pubmed: 29534462
J Cell Physiol. 2017 Sep;232(9):2373-2386
pubmed: 27714805
Cell Physiol Biochem. 2016;38(1):267-82
pubmed: 26784579
Diabetologia. 2013 Jan;56(1):10-21
pubmed: 23052058
Cardiovasc Res. 2002 Aug 1;55(2):261-9
pubmed: 12123765
Cell Metab. 2012 Jun 6;15(6):805-12
pubmed: 22682221
Int J Cardiol. 2016 Mar 15;207:165-7
pubmed: 26803235
J Biol Chem. 2015 Oct 23;290(43):26141-50
pubmed: 26350455
Circulation. 2002 Mar 5;105(9):1135-43
pubmed: 11877368
J Lipid Res. 2009 Jan;50(1):3-21
pubmed: 18952573
Eur Heart J. 2008 Jun;29(12):1516-22
pubmed: 18492680
J Biol Chem. 2009 Jan 30;284(5):3049-57
pubmed: 19064991
Exp Cell Res. 2016 Jan 15;340(2):198-204
pubmed: 26524506
N Engl J Med. 2008 Nov 27;359(22):2396-8
pubmed: 19038890
Horm Metab Res. 2004 Sep;36(9):601-6
pubmed: 15486810
Physiol Res. 2016;65(1):23-32
pubmed: 26596323
J Am Coll Cardiol. 2008 Nov 25;52(22):1793-9
pubmed: 19022158
Neuromuscul Disord. 2017 May;27(5):481-486
pubmed: 28258942
Circ Res. 2009 Aug 14;105(4):326-34
pubmed: 19608978
Circ Res. 2010 Jul 23;107(2):233-41
pubmed: 20522803
J Diabetes Res. 2019 Apr 4;2019:9489826
pubmed: 31089475
J Mol Endocrinol. 2014 Jun;52(3):R199-222
pubmed: 24577718
Science. 2006 May 5;312(5774):734-7
pubmed: 16675698
Clin Exp Pharmacol Physiol. 2011 Dec;38(12):879-87
pubmed: 21895738
Diabetes Care. 2011 May;34 Suppl 2:S371-9
pubmed: 21525485
Eur J Clin Invest. 2013 Nov;43(11):1203-23
pubmed: 24102389
Trends Endocrinol Metab. 2000 Jul;11(5):175-80
pubmed: 10856918
Nat Genet. 2007 Jan;39(1):28-30
pubmed: 17187067
J Biol Chem. 1991 May 5;266(13):8162-70
pubmed: 1902472
Cell Metab. 2010 Mar 3;11(3):194-205
pubmed: 20197052
Cells. 2019 Feb 21;8(2):
pubmed: 30795549
FASEB J. 2009 Nov;23(11):3865-73
pubmed: 19625659
Prog Lipid Res. 2011 Jan;50(1):14-27
pubmed: 21087632
Nucleic Acids Res. 2001 May 1;29(9):e45
pubmed: 11328886
Biochim Biophys Acta. 2016 Oct;1861(10):1500-12
pubmed: 26924251
Nat Rev Endocrinol. 2015 Jun;11(6):363-71
pubmed: 25850659
PLoS One. 2019 Jun 7;14(6):e0208156
pubmed: 31173592
Biochim Biophys Acta. 2016 Oct;1861(10):1513-24
pubmed: 26924249
Circulation. 2007 Sep 4;116(10):1170-5
pubmed: 17698735
Cell Metab. 2006 May;3(5):309-19
pubmed: 16679289
Magn Reson Med. 2003 Mar;49(3):417-23
pubmed: 12594743
Cardiovasc Res. 2020 Feb 1;116(2):339-352
pubmed: 31166588
Biochim Biophys Acta. 1998 Apr 22;1391(3):287-306
pubmed: 9555061
PLoS Genet. 2010 Dec 09;6(12):e1001239
pubmed: 21170305
J Endocrinol. 2017 Jun;233(3):R173-R184
pubmed: 28420707
Science. 2004 Nov 19;306(5700):1383-6
pubmed: 15550674
J Biol Chem. 2009 Jul 31;284(31):21077-89
pubmed: 19509298
Arch Med Sci. 2017 Jun;13(4):864-874
pubmed: 28721155
Atherosclerosis. 2012 Jan;220(1):122-7
pubmed: 22100250
J Clin Endocrinol Metab. 2016 Jul;101(7):2701-10
pubmed: 27045985